[go: up one dir, main page]

WO2008143879A3 - Vitamin e supplementation for reducing cardiovascular events in individuals with dm and the hp 2-2 genotype - Google Patents

Vitamin e supplementation for reducing cardiovascular events in individuals with dm and the hp 2-2 genotype Download PDF

Info

Publication number
WO2008143879A3
WO2008143879A3 PCT/US2008/006157 US2008006157W WO2008143879A3 WO 2008143879 A3 WO2008143879 A3 WO 2008143879A3 US 2008006157 W US2008006157 W US 2008006157W WO 2008143879 A3 WO2008143879 A3 WO 2008143879A3
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
individuals
cardiovascular events
supplementation
genotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/006157
Other languages
French (fr)
Other versions
WO2008143879A2 (en
Inventor
Andrew Levy
Noah Berkowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rappaport Family Institute for Research in the Medical Sciences
Synvista Therapeutics Inc
Original Assignee
Rappaport Family Institute for Research in the Medical Sciences
Synvista Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/798,488 external-priority patent/US20080044399A1/en
Application filed by Rappaport Family Institute for Research in the Medical Sciences, Synvista Therapeutics Inc filed Critical Rappaport Family Institute for Research in the Medical Sciences
Publication of WO2008143879A2 publication Critical patent/WO2008143879A2/en
Publication of WO2008143879A3 publication Critical patent/WO2008143879A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F1/00—Details not covered by groups G06F3/00 - G06F13/00 and G06F21/00
    • G06F1/24—Resetting means

Landscapes

  • Engineering & Computer Science (AREA)
  • Theoretical Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

This invention relates to methods and compositions of determining the benefit of therapy using vitamin - E for the treatment of cardiovascular events in individuals with diabetes melitus based on their Haptoglobin phenotype and the treatment of the cardiovascular events using vitamin-E based on the haptoglobin phenotype.
PCT/US2008/006157 2007-05-14 2008-05-14 Vitamin e supplementation for reducing cardiovascular events in individuals with dm and the hp 2-2 genotype Ceased WO2008143879A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/748,177 2003-12-31
US11/798,488 US20080044399A1 (en) 2000-04-20 2007-05-14 Vitamin E supplementation for reducing cardiovascular events in individuals with DM and the Hp 2-2 genotype
US74817707 2007-05-14

Publications (2)

Publication Number Publication Date
WO2008143879A2 WO2008143879A2 (en) 2008-11-27
WO2008143879A3 true WO2008143879A3 (en) 2009-01-22

Family

ID=86398036

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/006157 Ceased WO2008143879A2 (en) 2007-05-14 2008-05-14 Vitamin e supplementation for reducing cardiovascular events in individuals with dm and the hp 2-2 genotype

Country Status (1)

Country Link
WO (1) WO2008143879A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229244A1 (en) * 2000-04-20 2004-11-18 Rappaport Family Institute For Research In The Medical Sciences Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229244A1 (en) * 2000-04-20 2004-11-18 Rappaport Family Institute For Research In The Medical Sciences Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients

Also Published As

Publication number Publication date
WO2008143879A2 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
ZA200708361B (en) Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition
WO2008042231A3 (en) Compositions and methods for evaluating and treating heart failure
MX2009005935A (en) Chemical compounds and uses.
WO2009158033A3 (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
WO2008097277A3 (en) Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181
WO2008076437A3 (en) Activin-actrii antagonists and uses for increasing red blood cell levels
WO2008024473A3 (en) Mapping of genomic interactions
WO2011038155A3 (en) Genetic analysis
WO2010005982A3 (en) Multiplexed biomarkers of insulin resistance
WO2009120810A3 (en) Neurodegenerative disorders
EP2134245A4 (en) Unitary vision and coordination testing center
WO2009045505A3 (en) Prohormones for increasing sexual performance
WO2007122382A3 (en) Lycopene for the treatment of metabolic dysfunction
AU2007243282A8 (en) Compositions and methods for the treatment of cardiovascular disease
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
AP2011005599A0 (en) Reconstituted rice kernels and processes for theirpreparation.
EP2205771A4 (en) Method, alloy and component
EP2134246A4 (en) Unitary vision and neuro-processing testing center
WO2007084861A3 (en) Xenohormesis based compositions and methods
WO2009098355A8 (en) Novel use of probiotics
WO2009051232A1 (en) Method of determining autoinducer-2
WO2007038264A3 (en) Gapr-1 methods
WO2008143879A3 (en) Vitamin e supplementation for reducing cardiovascular events in individuals with dm and the hp 2-2 genotype
WO2007011757A8 (en) Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart
WO2011011733A3 (en) Factor replacement therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08754449

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08754449

Country of ref document: EP

Kind code of ref document: A2